Literature DB >> 2940957

Characterization of T cell subsets using monoclonal antibodies in nasopharyngeal carcinoma patients.

M M Hsu, B L Lin.   

Abstract

Peripheral blood T cell subsets from 99 patients with nasopharyngeal carcinoma (NPC), 38 age-matched healthy subjects, and 20 patients with head and neck cancer other than NPC were characterized by reactivity with monoclonal antibodies. Patients with NPC showed much lower values of percentage and absolute number of common T cells (OKT3+) and helper cells (OKT4+) (p less than 0.01) than the control groups. The percentage of suppressor cells (OKT8+) was found to be higher in NPC patients than in healthy persons (p less than 0.001), but the absolute number was still lower in NPC patients. A selective decrease in the ratios of OKT4+ to OKT8+ cells was found in NPC patients (p less than 0.001). The ratios were correlated inversely to the clinical stage (r = 0.294, p less than 0.01). After negative selection by complement-mediated cytolysis, the remaining cells were stimulated with phytohemagglutinin. Net counts of isotope incorporation were smaller in all T cell subsets of NPC patients (p less than 0.001). These data indicate that the depressed cell-mediated immunity in NPC patients is due to inadequate number and functions of T cell subsets and a relative increased proportion of suppressor T cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940957     DOI: 10.1177/000348948609500317

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  2 in total

1.  Increased morbidity from nasopharyngeal carcinoma and chronic pharyngitis or sinusitis among workers at a newspaper printing company.

Authors:  Y-H Liu; C-L Du; C-T Lin; C-C Chan; C-J Chen; J-D Wang
Journal:  Occup Environ Med       Date:  2002-01       Impact factor: 4.402

2.  A study of lymphocyte kinetics in nasopharyngeal carcinoma with indium III oxine-labelled lymphocytes.

Authors:  P N Cheng; W C Shiu; J O Leung; S K Ho; K K Wong; C Metreweli
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.